Fennec Pharmaceuticals Inc. (FENC) — 10-Q Filings

10-Q Filings (6)

• Fennec Narrows Q3 Loss on Strong PEDMARK Sales, Cash Declines — Nov 13, 2025 Risk: medium
  FENNEC PHARMACEUTICALS INC. reported a net loss of $638 thousand for the three months ended September 30, 2025, a significant improvement from the $5,735 thousa
• Fennec Pharma Narrows Q2 Loss, PEDMARK Sales Up Amidst Cash Burn — Aug 14, 2025 Risk: high
  FENNEC PHARMACEUTICALS INC. reported a net loss of $3.15 million for the three months ended June 30, 2025, an improvement from a net loss of $5.55 million in th
• Fennec Pharmaceuticals Files Q1 2025 10-Q — May 14, 2025 Risk: medium
  Fennec Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The company, located in Research Triangle Park, NC, operates in the biological
• Fennec Pharma Q3 2024: Assets Near Liabilities — Nov 8, 2024 Risk: medium
  Fennec Pharmaceuticals Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $27.422 million and total liabilities
• Fennec Pharma 10-Q: Assets Near Liabilities — Aug 13, 2024 Risk: medium
  Fennec Pharmaceuticals Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $27.3 million and total liabilities of $27.
• Fennec Pharmaceuticals Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: medium
  FENNEC PHARMACEUTICALS INC. (FENC) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Fennec Pharmaceuticals Inc. reported revenue of $2.71 million f

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX